MedTrace Logo

Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates

NCT02802982 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2024-05-16

No results posted yet for this study

Summary

Parents of infants who have been thrombocytopenic for 3-4 days will be approached for consent to enter the study. For the purposes of the study, thrombocytopenia will be defined as a platelet count \<60,000/uL or a platelet count \<100,000/uL that prompted a platelet transfusion. Following enrollment, the platelet count will be followed in each infant. Participants will enter the study if on day 5 or later after the onset of thrombocytopenia (defined as above) infants either have a platelet count \<60,000/uL or a platelet count \<100,000/uL for which a platelet transfusion is ordered.

Conditions

  • Neonatal Thrombocytopenia

Sponsors & Collaborators

Principal Investigators

  • Martha Sola-Visner, MD · Boston Children's Hospital

Eligibility

Min Age
5 Days
Max Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02802982 on ClinicalTrials.gov